source
- AVB-001 Cell Therapy Demonstrates Safety and Immune Activation in Platinum-Resistant Ovarian CancerAVB-001, an encapsulated interleukin-2 cell therapy, was evaluated in patients with platinum-resistant high-grade serous ovarian carcinoma. The study reported that the treatment was well tolerated.…
- Rintatolimod added to pembrolizumab and cisplatin yields 50% response rate in recurrent ovarian cancerA clinical study evaluated the combination of rintatolimod, pembrolizumab and cisplatin in patients with recurrent ovarian cancer. The regimen produced an objective response rate of 50%, indicatin…onclive · 5mo agoPositive readoutPositive